Search

Dan V Mourich

from Salem, OR
Age ~62
Get Report
Also known as:
Daniel V Mourich
Phone and address:
5340 Vitae Springs Rd S, Salem, OR 97306
(541) 905-6033
Related to:
Michelle Zaorski, 56Natalie J Kelley, 55Jon P Kelley, 55Jason C Carpenter, 51Donna M Carpenter, 76Charles T Carpenter, 78Jennifer L Carpenter, 52Dtd Carpenter
Connected to:
Gabriel A Mourik, 58Jennifer Mourikis, 45Nick M Mourikis, 79Paula Mourin, 42Arthur P Mourino, 81Edwin L Mourino, 38Keith A Mourino, 47Katherine A Mouris, 82Genee S Mouritsen, 77Hugh Mouritsen, 56

Dan Mourich Phones & Addresses

  • 5340 Vitae Springs Rd S, Salem, OR 97306 (541) 905-6033
  • Albany, OR
  • Beaverton, OR
  • 8109 Kensington Rd, Portland, OR 97223 (503) 892-2544
  • West Linn, OR
  • Corvallis, OR

Resumes

Resumes

Dan Mourich Photo 1

Director Of Immunology

View page
Location:
5340 Vitae Springs Rd south, Salem, OR 97306
Industry:
Biotechnology
Work:
Avi
Director of Immunology
Skills:
Biotechnology
Immunology
Molecular Biology
Drug Discovery
Infectious Diseases
Cell Culture
Biochemistry
Cell
Vaccines
Research
Flow Cytometry
Virology
In Vitro
Clinical Trials
Life Sciences
Pharmaceutical Industry
In Vivo
Translational Research
Cell Biology
Drug Development
Teaching
Microsoft Office
Languages:
English
Dan Mourich Photo 2

Dan Mourich

View page

Business Records

Name / Title
Company / Classification
Phones & Addresses
Dan V. Mourich
Director Information Technology
Biocorva Tech, LLC
Fish/Shellfish Farm
745 NW Van Buren Ave, Corvallis, OR 97330

Publications

Us Patents

Antisense Compound For Inducing Immunological Tolerance

View page
US Patent:
8008469, Aug 30, 2011
Filed:
Nov 15, 2007
Appl. No.:
11/941033
Inventors:
Dan V. Mourich - Albany OR, US
Hong M. Moulton - Corvallis OR, US
David J. Hinrichs - Lake Oswego OR, US
Patrick L. Iversen - Corvallis OR, US
Assignee:
AVI BioPharma Inc. - Corvallis OR
International Classification:
C07H 21/02
C07H 21/04
C12Q 1/68
A61K 31/70
US Classification:
536 245, 435 6, 536 231, 536 241, 514 44 A
Abstract:
A method and conjugate for selectively killing antigen-activated T cells are disclosed. The conjugate is composed of a substantially uncharged antisense compound targeted against the human cFLIP protein, and a reverse TAT (rTAT) polypeptide coupled covalently to the antisense compound. The rTAT polypeptide is effective to produce selective uptake of the conjugate into antigen-activated T cells, relative to the uptake of the conjugate into non-activated T cells. The cFLIP antisense compound causes activation induced cell death (AICD) of activated lymphocytes. The method is useful in treating transplantation rejection and autoimmune conditions.

Antisense Oligomers And Methods For Inducing Immune Tolerance And Immunosuppression

View page
US Patent:
8415313, Apr 9, 2013
Filed:
May 11, 2006
Appl. No.:
11/433033
Inventors:
Dan V. Mourich - Albany OR, US
Patrick L. Iversen - Corvallis OR, US
Dwight D. Weller - Corvallis OR, US
Assignee:
AVI BioPharma, Inc. - Corvallis OR
International Classification:
C12N 15/11
A61K 48/00
C07H 21/02
C07H 21/04
US Classification:
514 44A, 536 245
Abstract:
A method and composition for inducing human dendritic cells to a condition of reduced capacity for antigen-specific activation of T cells, and, in mature dendritic cells, increased production of extracellular IL-10 is disclosed. A population of dendritic cells is exposed to a substantially uncharged antisense compound, including partially positively charged, containing 12-40 subunits and a base sequence effective to hybridize to a target region within the sequence identified by SEQ ID NO:9, to form a duplex structure between the compound and transcript having a Tm of at least 45 C. Formation of the duplex blocks expression of full-length CD86 in the cells, which in turn leads to reduced capacity for antigen-specific activation of T cells, and, in mature dendritic cells, increased production of extracellular IL-10.

Immunosuppression Compound And Treatment Method

View page
US Patent:
8501704, Aug 6, 2013
Filed:
Nov 7, 2008
Appl. No.:
12/267437
Inventors:
Dan V. Mourich - Albany OR, US
Patrick L. Iversen - Corvallis OR, US
Dwight D. Weller - Corvallis OR, US
Assignee:
Sarepta Therapeutics, Inc. - Corvallis OR
International Classification:
C12N 15/11
A61K 48/00
C07H 21/02
C07H 21/04
US Classification:
514 44A, 536 245
Abstract:
Provided are methods and antisense oligonucleotide analogs for suppressing an immune response in a mammalian subject, for the treatment or prevention of an autoimmune condition or transplantation rejection. The oligonucleotide analogs provided herein comprise a targeting sequence complementary to a preprocessed CTLA-4 mRNA region that spans the splice junction between intron 1 and exon 2 of the preprocessed CTLA-4 mRNA. Also provided are methods of use, in which the oligonucleotides are effective, when administered to a subject, to form within host cells, a heteroduplex structure (i) composed of the preprocessed CTLA-4 mRNA and the oligonucleotide compound, (ii) characterized by a Tm of dissociation of at least 45 C. , and (iii) resulting in an increased ratio of processed mRNA encoding ligand-independent CTLA-4 to processed mRNA encoding full-length CTLA-4.

Antisense Compositions And Methods For Modulating Contact Hypersensitivity Or Contact Dermatitis

View page
US Patent:
8592386, Nov 26, 2013
Filed:
Dec 17, 2009
Appl. No.:
12/641159
Inventors:
Dan V. Mourich - Albany OR, US
Nikki B. Marshall - Corvallis OR, US
Patrick L. Iversen - Corvallis OR, US
Assignee:
Sarepta Therapeutics, Inc. - Corvallis OR
International Classification:
A61K 31/70
C07H 21/04
US Classification:
514 44A, 536 245
Abstract:
Provided are methods and compositions, including topical compositions, for inducing tolerance to a sensitizing agent known to provoke contact hypersensitivity in a subject. Included are methods of topically applying to the subject an effective amount of an antisense composition targeting the start site or splice site of a CFLAR mRNA.

Antisense Compound And Method For Selectively Killing Activated T Cells

View page
US Patent:
20050203041, Sep 15, 2005
Filed:
Sep 22, 2004
Appl. No.:
10/946881
Inventors:
Dan Mourich - Albany OR, US
Hong Moulton - Corvallis OR, US
David Hinrichs - Lake Oswego OR, US
Patrick Iversen - Corvallis OR, US
International Classification:
C12Q001/68
C07H021/02
A61K048/00
C07F009/6533
US Classification:
514044000, 435455000, 514081000, 536023100, 544081000
Abstract:
A method and conjugate for selectively killing antigen-activated T cells are disclosed. The conjugate is composed of a substantially uncharged antisense compound targeted against the human cFLIP protein, and a reverse TAT (rTAT) polypeptide coupled covalently to the antisense compound. The rTAT polypeptide is effective to produce selective uptake of the conjugate into antigen-activated T cells, relative to the uptake of the conjugate into non-activated T cells. The cFLIP antisense compound causes activation induced cell death (AICD) of activated lymphocytes. The method is useful in treating transplantation rejection and autoimmune conditions.

Method And Antisense Composition For Selective Inhibition Of Hiv Infection In Hematopoietic Cells

View page
US Patent:
20050222068, Oct 6, 2005
Filed:
Oct 21, 2004
Appl. No.:
10/971959
Inventors:
Dan Mourich - Albany OR, US
Patrick Iversen - Corvallis OR, US
Richad Bestwick - Corvallis OR, US
International Classification:
A61K048/00
A61K031/675
US Classification:
514044000, 514081000
Abstract:
A method and conjugate for selectively targeting activated hematopoietic cells, e.g., macrophage or T-lymphocyte cells, are disclosed. The conjugate is composed of a substantially uncharged antisense compound targeted against HIV, and a reverse TAT (rTAT) polypeptide coupled covalently to the antisense compound. The rTAT polypeptide is effective to produce selective uptake of the conjugate into activated, HIV-infected cells, e.g., activated, HIV-infected macrophage and T-lymphocyte cells. An exemplary embodiment of the invention provides an antisense compound directed to the HIV Vif gene, causing the production of defective HIV virions in an infected individual.

Antisense Oligomers And Methods For Inducing Immune Tolerance And Immunosuppression

View page
US Patent:
20050234002, Oct 20, 2005
Filed:
Jan 21, 2005
Appl. No.:
11/041164
Inventors:
Dan Mourich - Albany OR, US
Patrick Iversen - Corvallis OR, US
International Classification:
A61K048/00
A61K031/675
US Classification:
514044000, 514081000, 514085000
Abstract:
A method and composition for inducing human dendritic cells to a condition of reduced capacity for antigen-specific activation of T cells, and, in mature dendritic cells, increased production of extracellular IL-10 is disclosed. A population of dendritic cells is exposed to a substantially uncharged antisense compound containing 12-40 subunits and a base sequence effective to hybridize to an expression-sensitive region of a preprocessed or processed human CD86 transcript identified, in its processed form, by SEQ ID NO:33, to form a duplex structure between said compound and transcript having a Tm of at least 45 C. Formation of the duplex blocks expression of full-length CD86 in said cells, which in turn leads to reduced capacity for antigen-specific activation of T cells, and, in mature dendritic cells, increased production of extracellular IL-10.

Immunomodulating Compositions And Methods For Use In The Treatment Of Human Autoimmune Diseases

View page
US Patent:
20060240032, Oct 26, 2006
Filed:
Mar 30, 2006
Appl. No.:
11/395663
Inventors:
David Hinrichs - Lake Oswego OR, US
Dan Mourich - Albany OR, US
Patrick Iversen - Corvallis OR, US
International Classification:
A61K 39/00
US Classification:
424185100
Abstract:
A composition and method for treating an autoimmune condition are disclosed. The composition includes of an immunomodulating compound composed of a central amino acid core having a plurality of chemical attachment groups, and a plurality of antigenic peptides which are (i) associated with an auto-immune disorder and (ii) attached to the core groups with the same N-terminus to C-terminus orientation. The compound is carried in a pharmaceutically acceptable carrier. An exemplary compound has an octomeric polylysine core and eight antigenic peptides, such as the peptides identified by SEQ ID NOS: 1-11, attached thereto. The compound is effective in treating an autoimmune disorder, by administering to a subject in need of the treatment, a pharmaceutically effective amount of the compound.
Control profile
Dan V Mourich from Salem, OR, age ~62 Get Report